Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence
View abstract on PubMed
Summary
This summary is machine-generated.A new circulating tumor DNA (ctDNA) blood test shows similar colorectal cancer (CRC) screening re-participation rates to the fecal immunochemical test (FIT). Interventions boosting health activation and awareness could enhance sustained CRC screening adherence.
Area Of Science
- Oncology
- Preventive Medicine
- Biomarkers
Background
- Colorectal cancer (CRC) screening is vital for reducing mortality.
- Sustained participation is key to effective CRC screening programs.
- A novel circulating tumor DNA (ctDNA) blood test is being evaluated for CRC screening adherence.
Purpose Of The Study
- To compare the re-participation rates of a ctDNA blood test versus the fecal immunochemical test (FIT) for CRC screening.
- To identify predictors of sustained CRC screening in an Australian population.
Main Methods
- A randomized controlled trial extended phase involved South Australians initially screened with ctDNA (n=36) or FIT (n=547).
- Participants were offered the same screening test approximately 2 years later.
- Surveys collected demographic, psychosocial, and clinical data; predictors of re-participation were analyzed using chi-square, Wilcoxon tests, and logistic regression.
Main Results
- Re-participation rates were similar between the ctDNA blood test (61%) and FIT (66%) groups (P=0.6).
- CRC fatalism, health activation, and self-efficacy predicted repeated screening.
- Awareness of the test predicted repeated FIT-based screening.
Conclusions
- The ctDNA blood test may be a viable option for maintaining CRC screening adherence, especially for those not participating with FIT.
- Interventions targeting health activation and screening awareness can improve adherence to CRC screening programs.

